Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kymera Therapeutics, Inc.

< Previous 1 2 Next >
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Participate in Upcoming June Investor Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Tickers KYMR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.